The first patient has started Redwood Pharma’s RP501 treatment for dry eye
(Stockholm, Sweden, May 5, 2022) Redwood Pharma AB (publ) today announces that the first patient has been included in the company’s clinical trial of RP501 and has also started treatment. The RP501 medical device with its innovative thermogelling properties is expected to constitute an effective and unique addition to first-line treatment for patients suffering from dry eye disease. Redwood Pharma’s clinical trial is a single-center study that will be conducted at the Medical University of Vienna, Austria, under the guidance of Principal Investigator Prof. Gerhard Garhöfer. 60 patients